Aug 07, 2019 / 06:00PM GMT
Kyle William Rose - Canaccord Genuity Corp., Research Division - Senior Analyst
Great. So we're going to continue on with the MedTech team here. I want to thank everybody for joining us again. This is 39th installment of Canaccord's Global Growth Conference. I appreciate everyone's participation.
I'm Kyle Rose. I'm one of the MedTech analysts here at Canaccord. I covered the diabetes space. We're very excited to have with us DexCom this afternoon. DexCom is a leader in the glucose-monitoring segment of the diabetes space with what we view as really the best-in-class technology. So very excited to have with us Steve Pacelli, the Executive Vice President of Strategy and Corporate Development as well as Quentin Blackford, the CFO.
There's a lot going on in diabetes. And I think it's a very compelling space. Valuations are -- if there's not a lot of volatility, valuation are stretched. But when I take a step back and I look at the underlying fundaments of the market, and they've never been stronger, both patient additions and then also your underlying technology. So I think there's a lot
DexCom Inc at Canaccord Genuity Growth Conference Transcript
Aug 07, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers